Cardiovascular Risk Reduction: With the 2023 approval for reducing major adverse cardiovascular events, GLP-1 receptor agonists are now used within comprehensive cardiovascular risk-management strategies for patients with type 2 diabetes and established cardiovascular disease
Some people may also notice dehydration symptoms, like dizziness or lightheadedness
rhabdomyolysis and renal failure Dermatologic concerns : Reports of eruptive melanocytic nevi, atypical nevi, and melanoma in situ temporally associated with use
Start with Alternate Health Club today
Kanduri SR, Kovacic R, Skipper GR, Velez JCQ
However, these findings remain largely hypothetical in humans and require further validation in clinical studies